WA
Wanbury Ltd (WANBURY)
₹197.99
Mkt cap
₹779 Cr
P/E ratio
13.10
P/B
4.79
Div yield
0.00%
ROE
68.40%
ROCE
30.70%
EPS (TTM)
₹15.11
Book value
₹41
52W range
162–359
Sector
Healthcare
Price history
Previous close
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research [1]
NSE WANBURYBSE 524212
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−44.83% from high₹198
₹162+22.59% from low₹359
Current
₹197.99
Prev close
₹199.50
Day
−0.76%
Price performance
1D
−1.30%
1W
−12.55%
1M
−22.60%
3M
−31.26%
6M
−11.29%
1Y
−21.48%
YTD
−16.11%
Financials
Revenue, profit & margin
P/E ratio
13.1×
WANBURY is 62% below the sector median of 34.6×
WANBURY13.1×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 146.29 | 144.46 | 145.50 | 139.41 | 131.11 | 161.19 | 133.45 | 172.00 | 163.18 | 160.06 | 162.45 | 164.58 | 165.58 | |
| Expenses | 132.94 | 127.12 | 124.35 | 121.25 | 120.13 | 141.18 | 119.50 | 142.37 | 138.74 | 134.28 | 135.77 | 134.74 | 149.35 | |
| Operating Profit | 13.35 | 17.34 | 21.15 | 18.16 | 10.98 | 20.01 | 13.95 | 29.63 | 24.44 | 25.78 | 26.68 | 29.84 | 16.23 | |
| OPM % | 9.13% | 12.00% | 14.54% | 13.03% | 8.37% | 12.41% | 10.45% | 17.23% | 14.98% | 16.11% | 16.42% | 18.13% | 9.80% | |
| Other Income | 0.62 | 0.76 | 0.69 | 0.93 | 0.94 | 1.63 | 0.84 | 1.84 | 0.35 | 0.20 | 0.18 | -3.39 | 0.36 | |
| Interest | 5.79 | 7.67 | 8.26 | 7.46 | 7.59 | 10.15 | 10.17 | 9.04 | 7.54 | 7.12 | 7.26 | 8.06 | 7.97 | |
| Depreciation | 3.18 | 3.24 | 3.32 | 3.28 | 3.29 | 3.32 | 3.32 | 3.37 | 3.64 | 3.70 | 3.74 | 3.23 | 4.04 | |
| Profit before tax | 5.00 | 7.19 | 10.26 | 8.35 | 1.04 | 8.17 | 1.30 | 19.06 | 13.61 | 15.16 | 15.86 | 15.16 | 4.58 | |
| Tax % | 6.00% | -2.50% | -0.19% | 3.23% | 0.00% | 1.84% | 5.38% | -6.30% | 0.88% | -0.13% | 0.69% | -43.14% | 29.26% | |
| Net Profit | 4.69 | 7.36 | 10.27 | 8.08 | 1.04 | 8.02 | 1.22 | 20.26 | 13.49 | 15.18 | 15.76 | 21.70 | 3.24 | |
| EPS in Rs | 1.43 | 2.25 | 3.14 | 2.47 | 0.32 | 2.45 | 0.37 | 6.18 | 4.10 | 4.35 | 4.52 | 6.21 | 0.93 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +3.32% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 11 Aug '26◦ |
| Earnings day | +3.32% |
| +1 day | −1.26% |
| +5 days | +6.00% |
| +15 days | −3.66% |
| +30 days | −11.46% |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202643.01%Promoter
Promoters43.01%
FIIs0.89%0.30
DIIs0.06%0.06
Public56.04%0.35
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Wanbury | ₹222.75 | 13.13 | 779 | 0.00% | 3 | −75.98% | 166 | +1.47% | 30.66% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts4
Credit ratings4
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Sep - Newspaper Clipping - Information regarding 38th Annual General Meeting to be held through VC/OAVM.Notice Of Book Closure For The Purpose Of 38Th Annual General Meeting (AGM). 31 Aug - 38th AGM on 24 September 2026; book closure18 to 24 September 2026.Reg. 34 (1) Annual Report. 31 AugAnnual Report 2025-26 And Notice Of The 38Th Annual General Meeting Of Wanbury Limited. 31 Aug - Wanbury issued FY26 annual report and AGM notice; seeks 5-year reappointment of Whole-time Director Mohan Kumar Rayana.Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Aug - Newspaper Publication - Information regarding 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11.30 A.M.